TrialThe Lancet. Haematology2017

High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan.

Yago Nieto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.